Drugs Targeting EGFR

  • Gilotrif (afatinib) – approved for stage 4 NSCLC patients with a change in EGFR as detected by a biomarker test.
  • Iressa (gefitnib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.
  • Rybrevant (amivantamab-vmjw) – approved for stage 4 NSCLC with a change in EGFR called exon 20 insertion as detected by a biomarker test.
  • Tagrisso (osimertinib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test. Tagrisso is also approved for stage 4 NSCLC patients with the EGFR T790M change.
  • Tarceva (erlotinib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test. Tarceva is also approved in combination with Cyramza (ramucirumab) for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.
  • Vizimpro (dacomitinib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.